Quince Therapeutics to Present at A-T Clinical Research Conference, Highlights eDSP Data Analyses

Quince Therapeutics will participate in the 2025 A-T Clinical Research Conference, where KOLs will present data analyses from the company's prior Phase 3 ATTeST clinical trial of its lead asset, eDSP, for the treatment of patients with Ataxia-Telangiectasia. Quince management will also provide an overview of its pivotal Phase 3 NEAT clinical trial. The presentations will highlight metabolic and endocrine events, growth, and safety laboratory results in patients treated with eDSP, as well as the potential relationship between miniATM family expression and neurological scores in A-T patients.